In this episode, I’ll discuss how desmopressin (DDAVP) can be used for intracranial hemorrhage.
Neurocritical Care guidelines suggest consideration of a single dose of desmopressin (DDAVP) in intracranial hemorrhage associated with aspirin or ADP receptor inhibitors.
Desmopressin causes the release of von Willebrand factor and increases platelet adhesion. It has a low risk of serious side effects, and a relatively low cost.
DDAVP for anti-platelet reversal in intracranial hemorrhage has been reported in a handful of studies, usually at a dose of 0.4 mcg/kg IV. It appears DDAVP can stabilize platelet function, but the duration of effect is influenced by the amount and frequency of anti-platelet agent dosing. Repeat dosing of DDAVP may be required in some patients.
If you like this post, check out my book – A Pharmacist’s Guide to Inpatient Medical Emergencies: How to respond to code blue, rapid response calls, and other medical emergencies.
Leave a Reply